Alembic Pharma Receives USFDA EIR for Vadodara Bioequivalence Facility
Alembic Pharmaceuticals Ltd 路 Others (Uncategorized) 路 16 Sept 2026, 11:37 pm
Alembic Pharma Receives USFDA EIR for Vadodara Bioequivalence Facility Alembic Pharmaceuticals Limited announced that the US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR), successfully closing the inspection for its Bioequivalence Facility located at Vadodara, Gujarat. The regulatory audit was conducted between 3rd Mar'25 and 7th Mar'25. The receipt of the EIR confirms regulatory compliance and clears the facility of pending inspectional concerns.
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg. 路 15 Nov 2026
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. 路 10 Nov 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). 路 05 Nov 2026
- Please find attached Audio Recording of Investor Call. 路 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. 路 04 Nov 2026
- Please find attached Press Release 路 04 Nov 2026
- Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
